Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology : Official Journal of the European Society for Medical Oncology
E Gabriela ChioreanC J Sweeney

Abstract

Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth factor receptor-2 (VEGFR-2). An initial phase I study evaluated ramucirumab administered weekly in advanced cancer patients. This phase I study of ramucirumab [administered every 2 or 3 weeks (Q2W or Q3W)] examined safety, maximum tolerated dose, pharmacokinetics, immunogenicity, antitumor activity, and pharmacodynamics. Patients with advanced solid malignancies were treated with escalating doses of ramucirumab i.v. over 1 h. Blood was sampled for pharmacokinetics studies throughout treatment; levels of circulating vascular endothelial growth factor-A (VEGF-A) and soluble VEGF receptors (R)-1 and -2 were assessed. Twenty-five patients were treated with ramucirumab: 13 with 6, 8, or 10 mg/kg Q2W, and 12 with 15 or 20 mg/kg Q3W. The median treatment duration was 12 weeks (range 2-81). No dose-limiting toxicities were observed. The most frequently reported adverse events (AEs) included proteinuria and hypertension (n = 6 each), and diarrhea, fatigue and headache (n = 4 each). Treatment-related grade 3/4 AEs were: two grade 3 hypertension (10 and 20 mg/kg), one each grade 3 ...Continue Reading

References

Aug 3, 2002·Nature Reviews. Cancer·Steven A StackerKari Alitalo
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Feb 16, 2005·Cancer Cell·Marc G AchenSteven A Stacker
May 10, 2006·Biochemical and Biophysical Research Communications·Hua-Quan MiaoZhenping Zhu
Sep 20, 2006·The Journal of Investigative Dermatology·Leah N Cueni, Michael Detmar
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer L SpratlinS Gail Eckhardt
Jul 9, 2010·Clinical Pharmacokinetics·Ron J KeizerJos H Beijnen
May 23, 2013·Cancer Research·Annamari K AlitaloMichael Detmar
Jun 28, 2013·Expert Opinion on Biological Therapy·Jeffrey Melson Clarke, Herbert I Hurwitz
Oct 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew B NixonUNKNOWN Alliance for Clinical Trials In Oncology

❮ Previous
Next ❯

Citations

Jul 21, 2015·Expert Opinion on Biological Therapy·Lorenzo CalvettiEmilio Bria
Dec 30, 2015·Pharmacology & Therapeutics·Lyn M Moir
Feb 20, 2016·Expert Opinion on Drug Metabolism & Toxicology·Valentina GambardellaAndrés Cervantes
Sep 6, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah L Greig, Gillian M Keating
Aug 24, 2016·Current Colorectal Cancer Reports·Kristen K Ciombor, Richard M Goldberg
May 5, 2016·Expert Review of Anticancer Therapy·Asuncion Diaz-SerranoRocio Garcia-Carbonero
May 6, 2016·Expert Review of Clinical Pharmacology·Giuseppe AprileMario Scartozzi
Oct 1, 2016·Expert Review of Anticancer Therapy·Valérie PaulusMaurice Pérol
Apr 25, 2017·Future Oncology·Elena ElimovaJaffer A Ajani
May 5, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wang JinjunJiang Guixi
Apr 12, 2017·Expert Opinion on Drug Safety·Oscar ArrietaMariana Lopez-Mejia
Oct 12, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Matteo MorottiSimon Lord
Aug 5, 2017·Expert Opinion on Investigational Drugs·Mauricio P PintoMarcelo Garrido
Dec 13, 2017·Future Oncology·Panagiotis J VlachostergiosScott T Tagawa
Jun 17, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·A VennepureddyT Terjanian
May 31, 2016·Therapeutic Advances in Medical Oncology·Helena VerdaguerTeresa Macarulla
Aug 4, 2018·Expert Opinion on Drug Safety·Alba NogueridoJosep Tabernero
Mar 7, 2018·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kensei YamaguchiTaroh Satoh
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Letizia ProcaccioFotios Loupakis
Aug 24, 2017·British Journal of Clinical Pharmacology·Lisa O'BrienMichael Heathman
Mar 29, 2019·Expert Opinion on Biological Therapy·Celine DebeuckelaereFotios Loupakis
Jul 22, 2016·The Oncologist·Emilie M J van BrummelenJan H M Schellens
Feb 9, 2020·Drugs·Yahiya Y Syed
Jun 18, 2020·Cancer Management and Research·Emmanuele De LucaMassimo Di Maio
Feb 6, 2017·Japanese Journal of Clinical Oncology·Hiroshi NokiharaTomohide Tamura
Jul 21, 2017·Cardiovascular and Interventional Radiology·Chenyang ZhanJoseph P Erinjeri
Sep 29, 2020·Frontiers in Immunology·Mohamed A AlfalehAnwar M Hashem
Feb 19, 2016·Targeted Oncology·Amparo Sanchez-GastaldoRocío Garcia-Carbonero
May 22, 2019·Asia-Pacific Journal of Clinical Oncology·Shuichi Hironaka
Oct 31, 2019·World Journal of Gastrointestinal Oncology·Nicola PersoneniLorenza Rimassa
Jan 14, 2021·Current Treatment Options in Oncology·Eric P Borrelli, Conor G McGladrigan
Oct 14, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuDavid Planchard
Nov 3, 2020·Expert Review of Gastroenterology & Hepatology·Hui Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

© 2021 Meta ULC. All rights reserved